Entera Bio (FRA:5DT) Long-Term Capital Lease Obligation : €0.21 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Long-Term Capital Lease Obligation?

Entera Bio's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.21 Mil.

Entera Bio's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.25 Mil) to Dec. 2023 (€0.24 Mil) and declined from Dec. 2023 (€0.24 Mil) to Mar. 2024 (€0.21 Mil).

Entera Bio's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€0.11 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.24 Mil).

Entera Bio Long-Term Capital Lease Obligation Historical Data

The historical data trend for Entera Bio's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Long-Term Capital Lease Obligation Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.11

0.20

0.11

0.24

Entera Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.29	0.25	0.24	0.21

Entera Bio (FRA:5DT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Entera Bio Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Entera Bio's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ENTX:USA

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines